KalVista Pharmaceuticals rises after FDA nod for Ekterly

4 hours ago 1

• Healthcare
• On the Move

SweetBunFactory/iStock via Getty Images

• KalVista Pharmaceuticals (NASDAQ:KALV) shares climbed on Monday after the U.S. FDA approved its plasma inhibitor, Ekterly (sebetralstat), for the treatment of hereditary angioedema in adult and pediatric patients aged 12 years and older.
• KalVista said it will launch Ekterly in

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. KalVista Pharmaceuticals rises after FDA nod for Ekterly